Azetidine-substituted pyridine and pyrazine compounds as inhibitors of cannabinoid receptor 2
US-12180196-B2 · Dec 31, 2024 · US
Small molecule inhibitors of ebola and lassa fever viruses and methods of use
US9193705B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9193705-B2 |
| Application number | US-201113818790-A |
| Country | US |
| Kind code | B2 |
| Filing date | Sep 1, 2011 |
| Priority date | Sep 1, 2010 |
| Publication date | Nov 24, 2015 |
| Grant date | Nov 24, 2015 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to compositions and methods for the treatment of infection by enveloped viruses, such as Ebola and Lassa fever viruses.
First claim
Opening claim text (preview).
We claim: 1. A compound represented by formula II: or a pharmaceutically acceptable salt, solvate, hydrate, chemically-protected form, enantiomer or stereoisomer thereof; wherein, independently for each occurrence, L 1 is L 2 is l 1 is a bond to L 1 ; l 2 is a bond to L 2 ; a 1 is a bond to a 2 is a bond to a 3 is a bond to X is a bond, R 3 is hydrogen or alkyl; R 4 is hydrogen, alkyl, aralkyl, or alkylcarbonyl; and R 5 is hydrogen, or alkyl, haloalkyl, or alkyl substituted with hydroxy, cyano, carboxy, aralkyloxy, alkyloxycarbonyl or aralkyloxycarbonyl; provided that the compound is not 2. The compound of claim 1 , wherein 3. The compound of claim 1 , wherein 4. The compound of claim 1 , wherein 5. The compound of claim 1 , wherein 6. The compound of claim 1 , wherein and R 4 is alkyl. 7. The compound of claim 1 , wherein and X is 8. The compound of claim 1 , wherein and R 3 and R 5 are hydrogen. 9. The compound of claim 1 , wherein and X is a bond. 10. The compound of claim 1 , wherein X is a bond; and R 4 is alkyl. 11. The compound of claim 1 , wherein L 1 is 12. The compound of claim 1 , wherein L 1 is and X is a bond. 13. The compound of claim 1 , wherein L 2 is 14. The compound of claim 1 , wherein L 2 is and X is —CH 2 —.
Assignees
Inventors
Classifications
linked by a carbon chain containing only aliphatic carbon atoms · CPC title
Antivirals · CPC title
attached in position 4 · CPC title
directly linked by a ring-member-to-ring-member bond · CPC title
Radicals substituted by nitrogen atoms, not forming part of a nitro radical · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9193705B2 cover?
- The present invention relates to compositions and methods for the treatment of infection by enveloped viruses, such as Ebola and Lassa fever viruses.
- Who is the assignee on this patent?
- Cunningham James, Lee Kyungae, Ren Tao, and 3 more
- What technology area does this patent fall under?
- Primary CPC classification C07D401/04. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Nov 24 2015 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).